SCHEMBL20255018

SCHEMBL20255018

COc1c(C(=O)O)cc(Cl)c(C)c1-c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ HTT P42858 1/20 0.46
▸ DHODH Q02127 3/20 0.43
▸ MKNK1 Q9BUB5 2/20 0.43
▸ MKNK2 Q9HBH9 2/20 0.43
▸ CYP11B1 P15538 3/20 0.42
▸ CYP11B2 P19099 3/20 0.42
▸ EIF4E P06730 1/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP17A1 P05093 1/20 0.42
▸ PPARA Q07869 1/20 0.42
▸ ACLY P53396 2/20 0.41
▸ NR4A2 P43354 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29688687 1.00 LMNA (0.46) LMNAKDM4EHTTDHODHMKNK1
SCHEMBL29688594 0.81 AKR1C3 (0.44) MKNK1MKNK2CYP11B1CYP11B2ACLY
SCHEMBL20243515 0.81 AKR1C3 (0.44) MKNK1MKNK2CYP11B1CYP11B2ACLY
SCHEMBL29688422 0.78 CYP11B1 (0.39) KDM4EHTTCYP11B1CYP11B2CYP3A4
SCHEMBL30590299 0.78 CYP11B1 (0.39) KDM4EHTTCYP11B1CYP11B2CYP3A4
SCHEMBL20240859 0.78 CYP11B1 (0.39) KDM4EHTTCYP11B1CYP11B2CYP3A4
SCHEMBL29688628 0.77 POLB (0.39) KDM4EHTTCYP11B1CYP11B2CYP3A4
SCHEMBL30312124 0.76 HTT (0.49) LMNAKDM4EHTTDHODHMKNK1
SCHEMBL29688933 0.73 KDM4E (0.41) KDM4EHTTCYP11B1CYP11B2CYP3A4
SCHEMBL20254635 0.73 KDM4E (0.41) KDM4EHTTCYP11B1CYP11B2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2023-08-15 — — US disclosed
CN-114805366-A Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors 百济神州有限公司 2022-07-29 — — CN disclosed
CN-110267959-B Imidazo [1,5-A ] pyrazine derivatives as PI3K delta inhibitors 百济神州有限公司 2022-05-27 — — CN disclosed
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-03-31 — — US disclosed
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-03-31 — — US disclosed
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2021-10-05 — — US disclosed
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors BEIGENE, LTD. (KY) 2021-10-05 — — US disclosed
WO-2018103688-A1 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS BEIGENE, LTD. (KY) 2018-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098202-A1 IMIDAZO[1,5-a]PYRAZINE DERIVATIVES AS PI3K DELTA INHIBITORS PIK3CD, PIK3R5, PIK3CA LMNA 3992/4885KDM4E 3469/4885HTT 3689/4885
US-11136323-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA LMNA 4079/4885KDM4E 3721/4885HTT 3445/4885
US-11725012-B2 Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors PIK3CD, PIK3R5, PIK3CA LMNA 4188/4885KDM4E 3583/4885HTT 3524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback